RARE Stock Plunges As Ultragenyx Misses Key GTX-102 Trial

Ultragenyx Pharmaceutical Inc. stocks have been trading up by 3.57 percent following upbeat coverage of its rare disease pipeline.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading RARE

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

What Traders Need To Know

Genglycos (DTX401) won accelerated FDA approval in GSDIa with a $2.7M list price, prompting BofA to lift its Ultragenyx Pharmaceutical Inc. target to $48 and reaffirm a Buy rating.
Ninety‑six–week Phase 3 data for Genglycos showed a 61% cut in daily cornstarch use with maintained glycemic control and a manageable safety profile, backing the long‑term case for the gene therapy.
Major banks, including Morgan Stanley and Wells Fargo, had raised targets to $74 and $50, respectively, after approval, seeing Genglycos as Ultragenyx Pharmaceutical Inc.’s first key gene therapy win and expecting GTX‑102 data as a near‑term catalyst.
The GTX‑102 Aspire study in Angelman syndrome failed all primary and secondary endpoints, leading Citi and H.C. Wainwright to slash targets to $28 and $25, though both kept Buy ratings, viewing the selloff as overdone.
Shares of RARE crashed 44.6% intraday to $14.70 on the Aspire news, while Wedbush and William Blair turned more cautious, even as consensus targets around $33.95 still sit well above current trading.

Weekly Update Aug 31 – Sep 04, 2026: On Friday, September 04, 2026 Ultragenyx Pharmaceutical Inc. stock [NASDAQ: RARE] is trending up by 3.57%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – neutral

Ultragenyx (RARE) occupies a differentiated rare-disease and gene-therapy niche with strong 3‑yr revenue CAGR above 20% and exceptional 87.8% gross margin, but the business remains structurally loss‑making with EBIT margin near ‑80% and ROA around ‑45%. Cash burn is heavy (Q2 operating cash flow ‑$97M) despite $292M in cash and investments, and negative equity (retained losses ≈$4.8B) underscores cumulative dilution. The balance sheet has no long‑term debt but limited runway without further capital raises or a sharp profitability inflection from new launches.

Technically, RARE has transitioned from a stable mid‑$20s base (August closes around $25–26) to a violent breakdown following the GTX‑102 failure, with prints collapsing into the mid‑teens and a closing rebound to $15.35. Five‑minute tape shows capitulation volume on the gap‑down, then short‑covering rather than real accumulation. Dominant trend is now down with high volatility. $15 is the immediate pivot: below it, air pocket risk; above, tactical traders can target a bounce toward $18–19 with tight stops.

More Breaking News

The fundamental outlook is now binary around Genglycos execution and the broader pipeline after the GTX‑102 Phase 3 failure, which triggered a 45% one‑day drawdown and multiple target cuts (Citi to $28, Wainwright $25, Wedbush $23). Nonetheless, peers remain largely Overweight with a consensus target around $34, reflecting durable Genglycos data and strong pricing power in GSDIa. Versus biotech benchmarks, RARE is higher‑risk but also higher‑upside; fair value sits near $24–26 over 12–18 months, with support at $14 and resistance at $20 then $25.

Quick Financial Overview

Ultragenyx Pharmaceutical Inc. is a classic high‑risk biotech story: strong top‑line growth, but deep losses and heavy cash burn. Over the last quarter, the company generated $214M in revenue and $180M in gross profit, thanks to an 87.8% gross margin, yet it still posted a net loss of $92M. Operating cash flow came in at -$97M, with cash dropping from $189M to $140M, a reminder that the balance sheet must be watched closely by traders.

From a valuation angle, RARE trades at roughly 3.65 times trailing sales, with enterprise value near $1.17B on total revenue of about $673M. Negative book value and a profit margin around -81.7% show years of cumulative losses baked into the capital structure. However, a current ratio of 1.7 and quick ratio of 1.4 indicate Ultragenyx Pharmaceutical Inc. still has reasonable short‑term liquidity, at least for now.

On the chart, the stock collapsed from the mid‑$25s to the mid‑$15s in days, with a weekly low near $14.90 after the GTX‑102 failure and a modest bounce to roughly $15.35. Intraday, the 5‑minute tape shows heavy volatility early, then tight trading between about $15.20 and $15.80 into the close, signaling short‑term price discovery after the shock. For active traders, that $14.70–$15 zone now acts as an initial support band, with prior $25–$26 levels far above as a longer‑term gap area.

Conclusion

Ultragenyx Pharmaceutical Inc. is now trading like a broken momentum story that still has a real commercial asset underneath. Genglycos, with accelerated FDA approval and 96‑week Phase 3 data showing durable benefit and acceptable safety, gives the company a high‑priced, first‑in‑class gene therapy in GSDIa. At the same time, the GTX‑102 Aspire failure has ripped out a major part of the upside narrative and triggered a violent repricing, with RARE losing nearly half its value in a single session.

For traders, the key is to separate the emotional reaction from the hard numbers. As Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.” That mindset is critical here: detailed planning around key levels, catalysts, and risk parameters has to come before the open, not in the heat of a fast tape. Revenue growth, strong gross margins, and continued hiring signal an operating business that is still pushing forward, even as net losses and negative cash flow keep financing risk on the table. The stock now trades far below the roughly $33.95 mean analyst target, but that gap alone is not a signal; it is simply a measure of how far sentiment has swung.

Near term, price action around the $14.70–$15 band will tell you whether RARE is basing for a bounce or setting up for another leg lower. Any new data or commercial updates on Genglycos will likely drive the next sustained move. As I tell my students, “In names like Ultragenyx Pharmaceutical Inc., you do not get paid for being early or hopeful; you get paid for trading the levels the market actually respects.” This article is for educational and research purposes only. “,”scores”:{“risk-level”:”high”},”trade”:”true

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!